Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus-Reference-Cited by-同舟云学术

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

Published:2008-06 Issue:6 Volume:58 Page:1043-1046
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Murrell Dedee F.,Dick Sarah,Ahmed A.R.,Amagai Masayuki,Barnadas Maria A.,Borradori Luca,Bystryn Jean-Claude,Cianchini Giuseppe,Diaz Luis,Fivenson David,Hall Russell,Harman Karen E.,Hashimoto Takashi,Hertl Michael,Hunzelmann Nico,Iranzo Pilar,Joly Pascal,Jonkman Marcel F.,Kitajima Yasuo,Korman Neil J.,Martin Linda K.,Mimouni Daniel,Pandya Amit G.,Payne Aimee S.,Rubenstein David,Shimizu Hiroshi,Sinha Animesh A.,Sirois David,Zillikens Detlef,Werth Victoria P.

Publisher

Elsevier BV

Subject

Dermatology

Reference1 articles.

1. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus;Pfutze;Eur J Dermatol,2007

Cited by 445 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center;Medicina;2024-02-04

2. A Global View of Pemphigus: Geographical Variations;Clinical Reviews in Allergy & Immunology;2024-01-30

3. Are sites of primary lesions in pemphigus vulgaris more prone to relapse?;Oral Diseases;2024-01-29

4. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy;JAMA Dermatology;2024-01-24

5. Desmoglein autoantibodies and disease severity in pemphigus patients – correlations and discrepancies;Folia Medica;2023-12-31